Trial Profile
An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Taselisib (Primary) ; Fulvestrant; Letrozole; Midazolam
- Indications Advanced breast cancer; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Genentech
- 03 Sep 2021 Status changed from active, no longer recruiting to completed.
- 04 Nov 2020 Results published in the Clinical Cancer Research
- 07 Aug 2020 Status changed from recruiting to active, no longer recruiting.